今日港股回调，创新药再度逆市上涨！港股通创新药ETF（159570）强势大涨近3%，成交额继续爆量，盘中成交近5亿元！上周五成交额再度刷新历史，天 量成交16.49亿元！资金持续乐观，上周累计获资金净流入近2亿元，今日盘中再获净申购4300万份！ 港股通创新药ETF（159570）成分股多数飘红：乐普生物涨超12%，百济神州涨超5%，信达生物涨超3%，晶泰控股涨超2%，康方生物、药明生物、科伦博 泰生物涨超1%。 资金狂涌创新药，港股通创新药ETF（159570）近60日"吸金"近10亿元，融资余额保持历史高位，反映杠杆资金布局意愿！最新规模19.27亿元创上市新 高，1个月实现规模翻倍！ 【机构：医药见底回暖，创新药主线强化】 光大证券认为，医药行情见底回暖，优化集采政策有望稳定资产盈利能力。近期，医药行情整体已显现见底回暖迹象，从2025.1.2~2025.3.27期间，港股创 新药指数上涨26.28%，跑赢恒生科技1.20pp。2025年工作报告提出"优化药品集采政策"，有望优化产业竞争环境，仿制药利润压缩接近尾声，竞争格局趋于 稳定，龙头白马企业凭借技术壁垒与产能优势，盈利能力有望企稳。后集采时代，行 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 截至2024年12月31日止年度 全年業績公告 百濟神州有限公司連同其子公司（「本公司」或「百濟神州」或「我們」）謹此公佈本 公司截至2024年12月31日止年度（「報告期」）的綜合業績連同2023年相應期間的 比較數字，其乃根據美國公認會計原則（「美國公認會計原則」或「GAAP」）編製並 由本公司董事會（「董事會」）審計委員會（「審計委員會」）審閱。 財務摘要 1 • 截至2024年12月31日止年度的收入合計較截至2023年12月31日止年度增加 約14億美元或約55.0%至約38億美元。產品收入較截至2023年12月31日止 年度增加約16億美元或約72.6%至約38億美元。 • 截至2024年12月31日止年度的經營費用合計較截至2023年12月31日止年度 增加約497.8百萬美元或約15. ...

Financial Performance - Total revenue for the year ended December 31, 2024, increased by approximately $1.4 billion or about 55.0% to approximately $3.8 billion compared to the year ended December 31, 2023[3]. - Product revenue for the year ended December 31, 2024, increased by approximately $1.6 billion or about 72.6% to approximately $3.8 billion compared to the year ended December 31, 2023[3]. - Net loss for the year ended December 31, 2024, decreased by approximately $236.9 million or about 26.9% to approximately $644.8 million compared to the year ended December 31, 2023[3]. - Basic and diluted loss per share for the year ended December 31, 2024, was $0.47, a decrease of 27.7% from $0.65 for the year ended December 31, 2023[3]. - The operating loss for 2024 decreased by approximately $600 million compared to the previous year[13]. - The company reported a net loss of $644.8 million for the year ended December 31, 2024, compared to a net loss of $881.7 million in 2023, reflecting a reduction of approximately 26.9%[11]. - The company reported a net loss of $644,786,000 for the year ended December 31, 2024, compared to a net loss of $881,708,000 in 2023, reflecting an improvement in financial performance[102]. Revenue Breakdown - Total product revenue for the year ended December 31, 2024, was $4,786,744,000, a significant increase from $2,718,969,000 in 2023, representing a growth of approximately 76.1%[66]. - Net product revenue for the year ended December 31, 2024, was $3,779,546,000, compared to $2,189,852,000 in 2023, indicating a year-over-year increase of about 72.6%[66]. - Product revenue in the U.S. was $1,950,530,000 in 2024, compared to $945,551,000 in 2023, indicating a growth of about 106%[101]. - Product revenue in China increased to $1,390,699,000 in 2024 from $1,093,091,000 in 2023, marking a growth of approximately 27%[101]. - Global sales of Baiyueze® totaled $2.6 billion, representing a 104.9% year-over-year growth, with U.S. sales contributing $2 billion, up 106.3% from $945.6 million[130]. Expenses and Costs - Total operating expenses for the year ended December 31, 2024, increased by approximately $497.8 million or about 15.1% to approximately $3.8 billion compared to the year ended December 31, 2023[3]. - Research and development expenses for the year ended December 31, 2024, were approximately $1.95 billion, compared to approximately $1.78 billion for the year ended December 31, 2023[7]. - Sales and marketing expenses increased by $323.1 million (21.4%) to $1.8 billion, primarily due to ongoing investments in the commercialization of Baiyueze®[135]. - Adjusted cost of sales for products was $546.7 million for 2024, up 48.8% from $367.6 million in 2023[139]. - Total compensation cost for the year ended December 31, 2024, was $1.8 billion, up from $1.6 billion in 2023, reflecting increased labor costs[177]. Cash and Liquidity - Cash and cash equivalents as of December 31, 2024, were approximately $2.63 billion, down from approximately $3.17 billion as of December 31, 2023[4]. - The company has significant short-term and long-term cash needs, planning to utilize available cash to meet these obligations[158]. - Cash, cash equivalents, and restricted cash totaled approximately $2.64 billion as of December 31, 2024, down from $3.19 billion in 2023[150]. - The company reported a gross profit increase of $1.1 billion, driven by substantial revenue growth, although continued investments in pipeline development and global operations offset some of this growth[154]. Assets and Liabilities - Total assets as of December 31, 2024, were approximately $5.92 billion, compared to approximately $5.81 billion as of December 31, 2023[5]. - Total liabilities as of December 31, 2024, increased to approximately $2.59 billion from approximately $2.27 billion as of December 31, 2023[5]. - The total of accrued expenses and other payables rose by 15.9% to $803.7 million as of December 31, 2024, from $693.7 million in 2023, mainly due to increased sales allowances and returns[147]. - The total short-term debt amounted to $851,529,000 in 2024, compared to $688,366,000 in 2023, reflecting an increase of approximately 23.7%[59]. - The total long-term debt decreased to $166,484,000 in 2024 from $197,618,000 in 2023, showing a decline of about 15.8%[59]. Collaboration and Licensing - The company received a non-refundable upfront payment of $650 million from Novartis for the collaboration and licensing agreement related to the development and commercialization of Tislelizumab[24]. - Following the termination of the collaboration agreement with Novartis in September 2023, the company regained all global rights for Tislelizumab without any royalty obligations[25]. - The company confirmed collaboration revenue of $2.1 million related to Tislelizumab for the year ended December 31, 2024, compared to $77.3 million for the year ended December 31, 2023[26]. - The company reported total collaboration revenue of $30.7 million for the year ended December 31, 2024, a significant decrease of 88.6% compared to $268.9 million for the year ended December 31, 2023[23]. - The company has established various collaboration agreements for the research, development, and commercialization of drugs, which may include upfront payments, milestone payments, and profit-sharing arrangements[21]. Employee and Governance - The company has over 11,000 employees as of 2024, indicating growth since its establishment in 2010[14]. - The board of directors recommended not to declare any final dividend for the year ended December 31, 2024[180]. - The board of directors increased from 11 to 12 members, appointing Ms. Shalini Sharp as an independent non-executive director effective from September 27, 2024[186]. - The company has complied with all provisions of the corporate governance code during the reporting period[189]. - The company has adopted its own insider trading policy, which meets or exceeds the standards set forth in the Hong Kong Listing Rules[190]. Future Outlook - The company plans to achieve positive GAAP operating profit and operating cash flow in 2025[116]. - The company anticipates multiple innovative solid tumor projects to report data in the first half of 2025[120]. - The company plans to fully utilize the remaining net proceeds by 2026, based on actual business operations[195]. - The company is focusing on lifecycle management to maximize value for shareholders and patients in the hematologic oncology space[123]. - The company plans to expand the global reach of Baizean® through ongoing regulatory submissions and approvals, enhancing its commercialization capabilities[124].

Group 1 - The core viewpoint of the news is that BeiGene's stock closed down by 2.22%, with a latest price-to-book ratio of 12.59 and a total market capitalization of 304.24 billion yuan [1] - As of the third quarter of 2024, a total of 126 institutions hold shares in BeiGene, including 125 funds and 1 brokerage, with a total shareholding of 28.647 million shares valued at 4.613 billion yuan [1] - BeiGene is a global, commercial-stage biotechnology company focused on the research, development, production, and commercialization of innovative drugs, with key products including BRUKINSA (a BTK inhibitor), anti-PD-1 monoclonal antibody, and Pamiparib [1] Group 2 - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 19.136 billion yuan, representing a year-on-year increase of 48.63%, while the net profit was -3.686694 million yuan, a year-on-year change of 4.94%, with a gross margin of 83.94% [1] - BeiGene's price-to-earnings ratio (TTM) is reported at -61.11, with a static PE of -61.11 and a price-to-book ratio of 12.59, compared to the industry average PE of 39.48 and a price-to-book ratio of 7.28 [2] - The industry median PE is 35.25, with a median price-to-book ratio of 2.88, indicating that BeiGene's valuation metrics are significantly higher than the industry averages [2]

美股代码：ONC 百济神州有限公司 A 股代码：688235 A 股简称：百济神州 公告编号：2025-013 港股代码：06160 港股简称：百济神州 关于续聘2025年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任审计机构：安永华明会计师事务所（特殊普通合伙）为百济神州有 限公司（以下简称"公司"或"百济神州"）A 股财务报表和内部控制年度审 计机构；Ernst & Young（安永会计师事务所）为公司港股财务报表年度审计机 构；Ernst & Young LLP 为公司美股财务报表和内部控制年度审计机构。 一、续聘的审计机构的基本情况 （一）机构信息 1、安永华明会计师事务所（特殊普通合伙）（以下简称"安永华明"） （1）基本信息 安永华明于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合 作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。截至 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年3月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) 06160 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事 ...

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical industry [7] Core Insights - The report emphasizes the leadership of Chinese companies in the PD-(L)1 bispecific antibody sector, highlighting it as a representative technology platform for new drug development in China [21][13] - The overall performance of the pharmaceutical sector has shown a 1.77% increase, outperforming both the ChiNext Index and the CSI 300 Index during the week of March 10-14 [13][14] Summary by Sections Recent Performance - The market experienced an upward trend with a notable surge on Friday, reflecting a shift from technology to non-technology sectors, particularly in consumer healthcare and policies related to the three-child policy [2][14] - The report notes that while innovative drugs and AI healthcare showed signs of correction, other themes such as consumer healthcare and small-cap innovations in Hong Kong gained traction [2][14] Future Outlook - In the short to medium term, the focus is on identifying opportunities in consumer healthcare, particularly those with attributes appealing to children and those positioned for consumption upgrades [15] - For 2025, the report anticipates improvements in the pharmaceutical payment sector due to supportive policies for commercial health insurance, indicating a gradual accumulation of positive changes [15] Strategic Allocation Thoughts - The report outlines two main strategies for investment: 1. **Pharmaceutical Style Rhythm**: Focus on consumer healthcare companies like Angelalign and Aier Eye Hospital, and innovative drug companies such as Innovent Biologics and BeiGene [16] 2. **Pharmaceutical Industry Logic**: Emphasizes the commercialization of innovative drugs and the integration of new technologies, with a focus on companies like CStone Pharmaceuticals and Zymeworks [17][19] Key Companies to Watch - The report suggests monitoring companies involved in PD-(L)1 bispecific antibodies, including CanSino Biologics, Innovent Biologics, and I-Mab Biopharma, as they are positioned at the forefront of clinical advancements [21][34]

審計委員會會議日期 百濟神州有限公司（「本公司」）謹此公佈，本公司董事會（「董事會」）審計委員會 會議將於2025年3月27日（香港時間）舉行，以（其中包括）審議及批准本公司及其 附屬公司截至2024年12月31日止全年業績及根據香港聯合交易所有限公司證券上 市規則（「香港上市規則」）刊發全年業績。本公司先前於2025年2月27日公佈其截 至2024年12月31日止全年業績，並以提交表格10-K的方式將其全年業績送交美國 證券交易委員會（「美國證券交易委員會」）存案。本公司根據香港上市規則刊發的 全年業績與本公司先前已公佈並送交美國證券交易委員會存案者相同，惟根據香 港上市規則所要求的指定附加資料及將本公司的全年業績從美國公認會計原則與 國際財務報表準則進行核對的結果除外。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 香港，2025年3月14日 ...

如該公告所披露，2018員工購股計劃使合資格僱員可按市價15%折讓申購股份 （包括以美國存託股份的形式）。僱員可於認購期結束後購買股份，購股資金可從 其認購期內所得薪金中扣除。 公司謹此向其股東告知並宣佈，截至2024年9月3日至2025年2月28日之認購期的 最後一日，合共73,492股美國存託股份由3,356名參與者根據2018員工購股計劃購 買（「所購美國存託股份」）。所購美國存託股份涉及的股份數目為955,396，代表於 本公告之日本公司已發行股份總數的約0.068%。所購美國存託股份的詳情載列如 下： 授出日期╱認購期首日： 2024年9月3日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 員工購股計劃項下的股份購買及澄清公告 員工購股計劃項下的股份購買 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。茲提述本公 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年3月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事 ...